Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches
Headache and/or migraine, a common problem in pediatrics and internal medicine, affect about 5% to 10% children and adolescents, and nearly 30% of middle-aged women. Headache is also one of the most common clinical manifestations of acquired Toxoplasma gondii infection of the central nervous system...
Saved in:
Published in | American journal of therapeutics Vol. 14; no. 1; p. 63 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
01.01.2007
|
Subjects | |
Online Access | Get more information |
ISSN | 1075-2765 |
DOI | 10.1097/01.mjt.0000208272.42379.aa |
Cover
Loading…
Abstract | Headache and/or migraine, a common problem in pediatrics and internal medicine, affect about 5% to 10% children and adolescents, and nearly 30% of middle-aged women. Headache is also one of the most common clinical manifestations of acquired Toxoplasma gondii infection of the central nervous system (CNS) in immunosuppressed subjects. We present 11 apparently nonhuman immunodeficiency virus-infected children aged 7 to 17 years (8 girls, 3 boys) and 1 adult woman with recurrent severe headaches in whom latent chronic CNS T. gondii infection not manifested by enlarged peripheral lymph nodes typical for toxoplasmosis, was found. In 7 patients, the mean serum IgG Toxoplasma antibodies concentration was 189 +/- 85 (SD) IU/mL (range 89 to 300 IU/mL), and in 5 other subjects, the indirect fluorescent antibody test titer ranged from 1:40 to 1:5120 IU/mL (n= <1:10 IU/mL). Some of the patients suffered also from atopic dermatitis (AD) and were exposed to cat and/or other pet allergens, associated with an increased IL-4 and decreased IFN-gamma production. These cytokine irregularities caused limited control of cerebral toxoplasmosis probably because IL-4 down-regulated both the production of IFN-gamma and its activity, and stimulated production of a low NO-producing population of monocytes, which allowed cysts rupture, increased parasite multiplication and finally reactivation of T. gondii infection. The immune studies performed in 4 subjects showed a decreased percentage of T lymphocytes, increased total number of lymphocytes B and serum IgM concentration, and impaired phagocytosis. In addition, few of them had also urinary tract diseases known to produce IL-6 that can mediate immunosuppressive functions, involving induction of the anti-inflammatory cytokine IL-10. These disturbances probably resulted from the host protective immune reactions associated with the chronic latent CNS T. gondii infection/inflammation. This is consistent with significantly lower enzyme indoleamine 2,3-dioxygenase (IDO) activity reported in atopic than in nonatopic individuals, and an important role that IDO and tryptophan degradation pathways plays in both, the host resistance to T. gondii infection and its reactivation. Analysis of literature information on the subjects with different types of headaches caused by foods, medications, and other substances, may suggest that their clinical symptoms and changes in laboratory data result at least in part from interference of these factors with dietary tryptophan biotransformation pathways. Several of these agents caused headache attacks through enhancing NO production via the conversion of arginine to citrulline and NO by the inducible nitric oxide synthase enzyme, which results in the high-output pathway of NO synthesis. This increased production of NO is, however, quickly down-regulated by NO itself because this biomolecule can directly inactivate NOS, may inhibit Ia expression on IFN-gamma-activated macrophages, which would limit antigen-presenting capability, and block T-cell proliferation, thus decreasing the antitoxoplasmatic activity. Moreover, NO inhibits IDO activity, thereby suppressing kynurenine formation, and at least one member of the kynurenine pathway, 3-hydroxyanthranilic acid, has been shown to inhibit NOS enzyme activity, the expression of NOS mRNA, and activation of the inflammatory transcription factor, nuclear factor-kB. In addition, the anti-inflammatory cytokines IL-4 and IL-10, TGF-beta, and a cytokine known as macrophage deactivating factor, have been shown to directly modulate NO production, sometimes expressing synergistic activity. On the other hand, IL-4 and TGF-beta can suppress IDO activity in some cells, for example human monocytes and fibroblasts, which is consistent with metabolic pathways controlled by IDO being a significant contributor to the proinflammatory system. Also, it seems that idiopathic intracranial hypertension, pseudotumor cerebri, and aseptic meningitis, induced by various factors, may result from their interference with IDO and inducible nitric oxide synthase activities, endogenous NO level, and cytokine irregularities which finally affect former T. gondii status 2mo in the brain. All these biochemical disturbances caused by the CNS T. gondii infection/inflammation may also be responsible for the relationship found between neurologic symptoms, such as headache, vertigo, and syncope observed in apparently immunocompetent children and adolescents, and physical and psychiatric symptoms in adulthood. We therefore believe that tests for T. gondii should be performed obligatorily in apparently immunocompetent patients with different types of headaches, even if they have no enlarged peripheral lymph nodes. This may help to avoid overlooking this treatable cause of the CNS disease, markedly reduce costs of hospitalization, diagnosis and treatment, and eventually prevent developing serious neurologic and psychiatric disorders. |
---|---|
AbstractList | Headache and/or migraine, a common problem in pediatrics and internal medicine, affect about 5% to 10% children and adolescents, and nearly 30% of middle-aged women. Headache is also one of the most common clinical manifestations of acquired Toxoplasma gondii infection of the central nervous system (CNS) in immunosuppressed subjects. We present 11 apparently nonhuman immunodeficiency virus-infected children aged 7 to 17 years (8 girls, 3 boys) and 1 adult woman with recurrent severe headaches in whom latent chronic CNS T. gondii infection not manifested by enlarged peripheral lymph nodes typical for toxoplasmosis, was found. In 7 patients, the mean serum IgG Toxoplasma antibodies concentration was 189 +/- 85 (SD) IU/mL (range 89 to 300 IU/mL), and in 5 other subjects, the indirect fluorescent antibody test titer ranged from 1:40 to 1:5120 IU/mL (n= <1:10 IU/mL). Some of the patients suffered also from atopic dermatitis (AD) and were exposed to cat and/or other pet allergens, associated with an increased IL-4 and decreased IFN-gamma production. These cytokine irregularities caused limited control of cerebral toxoplasmosis probably because IL-4 down-regulated both the production of IFN-gamma and its activity, and stimulated production of a low NO-producing population of monocytes, which allowed cysts rupture, increased parasite multiplication and finally reactivation of T. gondii infection. The immune studies performed in 4 subjects showed a decreased percentage of T lymphocytes, increased total number of lymphocytes B and serum IgM concentration, and impaired phagocytosis. In addition, few of them had also urinary tract diseases known to produce IL-6 that can mediate immunosuppressive functions, involving induction of the anti-inflammatory cytokine IL-10. These disturbances probably resulted from the host protective immune reactions associated with the chronic latent CNS T. gondii infection/inflammation. This is consistent with significantly lower enzyme indoleamine 2,3-dioxygenase (IDO) activity reported in atopic than in nonatopic individuals, and an important role that IDO and tryptophan degradation pathways plays in both, the host resistance to T. gondii infection and its reactivation. Analysis of literature information on the subjects with different types of headaches caused by foods, medications, and other substances, may suggest that their clinical symptoms and changes in laboratory data result at least in part from interference of these factors with dietary tryptophan biotransformation pathways. Several of these agents caused headache attacks through enhancing NO production via the conversion of arginine to citrulline and NO by the inducible nitric oxide synthase enzyme, which results in the high-output pathway of NO synthesis. This increased production of NO is, however, quickly down-regulated by NO itself because this biomolecule can directly inactivate NOS, may inhibit Ia expression on IFN-gamma-activated macrophages, which would limit antigen-presenting capability, and block T-cell proliferation, thus decreasing the antitoxoplasmatic activity. Moreover, NO inhibits IDO activity, thereby suppressing kynurenine formation, and at least one member of the kynurenine pathway, 3-hydroxyanthranilic acid, has been shown to inhibit NOS enzyme activity, the expression of NOS mRNA, and activation of the inflammatory transcription factor, nuclear factor-kB. In addition, the anti-inflammatory cytokines IL-4 and IL-10, TGF-beta, and a cytokine known as macrophage deactivating factor, have been shown to directly modulate NO production, sometimes expressing synergistic activity. On the other hand, IL-4 and TGF-beta can suppress IDO activity in some cells, for example human monocytes and fibroblasts, which is consistent with metabolic pathways controlled by IDO being a significant contributor to the proinflammatory system. Also, it seems that idiopathic intracranial hypertension, pseudotumor cerebri, and aseptic meningitis, induced by various factors, may result from their interference with IDO and inducible nitric oxide synthase activities, endogenous NO level, and cytokine irregularities which finally affect former T. gondii status 2mo in the brain. All these biochemical disturbances caused by the CNS T. gondii infection/inflammation may also be responsible for the relationship found between neurologic symptoms, such as headache, vertigo, and syncope observed in apparently immunocompetent children and adolescents, and physical and psychiatric symptoms in adulthood. We therefore believe that tests for T. gondii should be performed obligatorily in apparently immunocompetent patients with different types of headaches, even if they have no enlarged peripheral lymph nodes. This may help to avoid overlooking this treatable cause of the CNS disease, markedly reduce costs of hospitalization, diagnosis and treatment, and eventually prevent developing serious neurologic and psychiatric disorders. |
Author | Prandota, Joseph |
Author_xml | – sequence: 1 givenname: Joseph surname: Prandota fullname: Prandota, Joseph email: Prandota@ak.am.wroc.pl organization: Faculty of Medicine and Dentistry, University Medical School, Wroclaw, Poland. Prandota@ak.am.wroc.pl |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17303977$$D View this record in MEDLINE/PubMed |
BookMark | eNo1Udtu1TAQNFIRvdBfqCzek_qSxAlvqIIWqVIlBM_Vxtk0Port4AuQv8fnQPdlV6vZ2RnNJTlz3iEhHzirORvULeO1PaSalRKsF0rUjZBqqAHOyAVnqq2E6tpzchnjgTEuet68I-dcSSYHpS7eXH9DnUNAl-iCMIFekEKkqTQLxtG42y15S_1MQf_MJuBENQYcA6w0-T9-WyFaH02kBV3ELdmCo8ba7PyEs9EGnd7pLxNyrIybUadCEfN4KFOkv01ayhldy58FJnR-g7TsH08KNggQTTpK2emINGDcvItmXJHOPpwwDnPwL-iMLgLmFayFZLyjm48pr3B8VvwA1ZAjHm1MZp7xZDjtG8bj6tV5fE_ezrBGvP7fr8iPL5-_3z1Uj0_3X-8-PVZaSJEqKaWS_TA0vJk7PvWDbDvGFB_6ptNajM3AO9kpGJq-bcWELYqSTCdUwUgBk7giN_94tzxanJ63YCyE_fk1F_EXvp6ZDA |
CitedBy_id | crossref_primary_10_1016_S0031_3939_09_70110_6 crossref_primary_10_3109_00207450903149217 crossref_primary_10_1007_s00436_024_08156_7 crossref_primary_10_1097_MAJ_0b013e31819f8cac crossref_primary_10_1177_1533317513517049 crossref_primary_10_1016_j_rasd_2009_09_007 crossref_primary_10_1155_2021_6634807 crossref_primary_10_1016_j_rasd_2009_09_011 crossref_primary_10_1371_journal_pone_0090203 crossref_primary_10_17116_jnevro20171175194_102 crossref_primary_10_3389_fpsyt_2024_1465381 crossref_primary_10_1016_S0031_3939_10_70064_0 crossref_primary_10_1038_nrd3793 crossref_primary_10_1016_S0031_3939_08_70202_6 crossref_primary_10_1016_j_schres_2011_08_006 crossref_primary_10_1080_00207450802480044 crossref_primary_10_1177_0883073810370480 crossref_primary_10_1016_S0031_3939_09_70176_3 crossref_primary_10_1016_j_rasd_2010_03_009 crossref_primary_10_1371_journal_pone_0018289 crossref_primary_10_2174_1871526520666200617135851 crossref_primary_10_3109_00207450903458647 crossref_primary_10_1186_1756_3305_6_113 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/01.mjt.0000208272.42379.aa |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 17303977 |
Genre | Journal Article |
GroupedDBID | --- .Z2 0R~ 23M 354 4Q1 4Q2 4Q3 53G 5GY 5VS 6J9 71W 8L- AAAAV AAHPQ AAIQE AARTV AASCR AAWTL AAYOK ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AEETU AENEX AFDTB AHQNM AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 C45 CAG CGR COF CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 L-C NPM N~M O9- OAG OAH OCUKA ODA OHH OJAPA OLG OLW OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W XXN XYM YFH ZFV ZZMQN |
ID | FETCH-LOGICAL-c232t-33373899414f61d8935600719846cc2b4916367a948552de5e227262707132ad2 |
ISSN | 1075-2765 |
IngestDate | Wed Feb 19 01:43:45 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c232t-33373899414f61d8935600719846cc2b4916367a948552de5e227262707132ad2 |
PMID | 17303977 |
ParticipantIDs | pubmed_primary_17303977 |
PublicationCentury | 2000 |
PublicationDate | 2007 Jan-Feb |
PublicationDateYYYYMMDD | 2007-01-01 |
PublicationDate_xml | – month: 01 year: 2007 text: 2007 Jan-Feb |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | American journal of therapeutics |
PublicationTitleAlternate | Am J Ther |
PublicationYear | 2007 |
SSID | ssj0012814 |
Score | 1.8981613 |
SecondaryResourceType | review_article |
Snippet | Headache and/or migraine, a common problem in pediatrics and internal medicine, affect about 5% to 10% children and adolescents, and nearly 30% of middle-aged... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 63 |
SubjectTerms | Adolescent Adult Child Female Headache Disorders, Secondary - etiology Humans Hypersensitivity, Immediate - complications Hypersensitivity, Immediate - immunology Immunocompetence Male Neurogenic Inflammation - complications Neurogenic Inflammation - immunology Neurogenic Inflammation - parasitology Recurrence Sex Factors Toxoplasmosis, Cerebral - complications Toxoplasmosis, Cerebral - diagnosis Toxoplasmosis, Cerebral - immunology |
Title | Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neurogenic inflammation postulated as a cause of different types of headaches |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17303977 |
Volume | 14 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB67CiKI6Hq_cR5kX7opzSRNGt9ElEVYKdKFfVsmkwS7NE3ZpGL88eJ3ZpI023Xx8hJKrjM5X0--M3PmO0K8iQJfTSZSOePU044_1bGjOHFtrLIILCmdalNs4vhzcHTifzqdnA4GP3tZS5sqHukfv11X8j9WxT7YlVfJ_oNlu5tiB37DvtjCwtj-lY2_8GC5kVeCS01YmpnLxjCVzBHwD8s6X1dFbqb6NWf8glzq9IKnipfgnN-LNahzXrAkCc5eFStbsG_BS0aKJGVtCbMw89viYlM6Nm0Ltyg38bnJATFjuKtiuMRzvio4sILrG9dtqgirivPcNBpTD2Muz9Kk4y7TLrnRyGmifwvNaWFAp11JOVwXZcWFxfA49EgNtdrYSYe2oEtlBo_Lhuuavpd9ot3NRPWkMXprzbpIYoZvNQJz1ZsN6Y-DhL1xEOu6QX4cGdrKE51v969g2Dpq61WvfD-sLvHYHeXnlZG2lKBIoRxx8lA0Uqp_Ed7mOjfIcuEmmUj_-eiOtnd7aE_sIcrhsq081tTMgcmpUabv-tVK5rLk6LUNZBHc5qY7gZIhTPP74l4T6dA7C9sHYpCu9sXt4yaXY18czKxqen1I855hDumAZls99frhjbsdzKk1NamSYE1imFMDcyoyamFOLczpEswJZ7cwp12Y02WYUwtzYpjjMtqB-VvTghbkaEpNcUo9kBNAbs7Zgpz6IKctyLk_igzIuRsdyMmAnHd1IH8kTj5-mL8_cpoqJo5GtFI5nsfiYVHku34WuAniAw4yQjcC89daxj4CNC8IlZFpkkk6SSUMGsiQx4-kSuRjcROvJn0qCMRyrKfKlXHi-WEcKC_WKojiKPOiDDTzmXhiLX62tlI1Zy0Wnl975IW4s_03vRS3MvjG9BWIdhW_Nnj8BaUO4Q4 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recurrent+headache+as+the+main+symptom+of+acquired+cerebral+toxoplasmosis+in+nonhuman+immunodeficiency+virus-infected+subjects+with+no+lymphadenopathy%3A+the+parasite+may+be+responsible+for+the+neurogenic+inflammation+postulated+as+a+cause+of+different+types+of+headaches&rft.jtitle=American+journal+of+therapeutics&rft.au=Prandota%2C+Joseph&rft.date=2007-01-01&rft.issn=1075-2765&rft.volume=14&rft.issue=1&rft.spage=63&rft_id=info:doi/10.1097%2F01.mjt.0000208272.42379.aa&rft_id=info%3Apmid%2F17303977&rft_id=info%3Apmid%2F17303977&rft.externalDocID=17303977 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1075-2765&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1075-2765&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1075-2765&client=summon |